While chemically synthesized peptides are excellent tools, the in-house production of peptides using bacteria offers clear advantages and great flexibility regarding mutational analysis and the use of additional (removable) tags to: promote cellular uptake; to perform affinity purifications; and to analyze via Western-blotting analysis and immunocytochemistry.
In this webinar we emphasize our work with peptides and present an alternative strategy to generating peptides using custom MiniGene synthesis from IDT. We share our experiences with this system, providing a balanced opinion towards this alternative method with its advantages and disadvantages. In particular, We provide more details about our endeavors to produce purified BH4 domain of Bcl-2 (and mutant forms of this peptides) using recombinant expression in E. coli by MiniGene synthesis.
About the Speaker
Professor Geert Bultynck received his PhD in 2001 from the Katholieke Universiteit in Leuven, Belgium for work on binding of immunophilines to intracellular Ca2+ release channel proteins (Humbert De Smedt laboratory). After several postdoctoral fellowships, including one at Stanford University (USA), to address calcineurin and apoptosis targets and Ca2+ channels in neurons, he returned to Belgium to start his own research group. In October 2008, he was appointed Professor at Katholieke Universiteit Leuven, in Belgium. His recent work involves the characterization of i) anti-apoptotic Bcl-2-family members in pro-survival Ca2+ signaling, ii) Bax Inhibitor-1 in ER Ca2+, iii) IP3R/Bcl-2 complexes in cancer cells, iv) IP3Rs in autophagy, and v) connexin hemi-channel activity. Along with 3 other principle investigators, Dr Bultynck leads a very motivated team of 2 post docs, 5 PhD students, and 2 technicians. His work is supported by numerous competitive grants from The Research Foundation Flanders and The Research Council of Katholieke Universiteit Leuven.